ABG
Ally Bridge Group Portfolio holdings
AUM
$114M
This Quarter Return
+16.53%
1 Year Return
+41.64%
3 Year Return
+246.39%
5 Year Return
–
10 Year Return
–
AUM
$114M
AUM Growth
+$114M
(+11%)
Cap. Flow
+$2.77M
Cap. Flow
% of AUM
2.42%
Top 10 Holdings %
Top 10 Hldgs %
67.79%
Holding
35
New
8
Increased
9
Reduced
5
Closed
11
Top Buys
| 1 |
LENZ
LENZ Therapeutics
LENZ
|
$10.1M |
| 2 |
Oric Pharmaceuticals
ORIC
|
$4.93M |
| 3 |
Replimune Group
REPL
|
$4.91M |
| 4 |
Soleno Therapeutics
SLNO
|
$4.89M |
| 5 |
CMPS
Compass Pathways
CMPS
|
$4.16M |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$12.4M |
| 2 |
Axsome Therapeutics
AXSM
|
$8.41M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$6.57M |
| 4 |
Trevi Therapeutics
TRVI
|
$4.32M |
| 5 |
Insmed
INSM
|
$3.76M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
Verona Pharma
VRNA
$9.16B
| $15.2M | 12.65% |
160,701
+21,634
| +16% | +$2.05M |
|
|
2
Soleno Therapeutics
SLNO
$3.6B
| $15M | 12.47% |
178,819
+58,370
| +48% | +$4.89M |
|
|
LENZ
3
LENZ Therapeutics
LENZ
$1.1B
| $10.1M | 8.37% |
+343,322
| New | +$10.1M |
|
4
Merus
MRUS
$4.98B
| $7.37M | 6.14% |
140,208
+62,312
| +80% | +$3.28M |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $5.64M | 4.7% |
281,394
+111,620
| +66% | +$2.24M |
|
|
6
Oric Pharmaceuticals
ORIC
$994M
| $4.93M | 4.1% |
+485,629
| New | +$4.93M |
|
|
7
Replimune Group
REPL
$422M
| $4.91M | 4.09% |
+528,491
| New | +$4.91M |
|
8
Tarsus Pharmaceuticals
TARS
$2.47B
| $4.91M | 4.08% |
121,182
-6,750
| -5% | -$273K |
|
|
9
Insmed
INSM
$28.8B
| $4.8M | 4% |
47,710
-37,400
| -44% | -$3.76M |
|
10
MindMed
MNMD
$676M
| $4.71M | 3.92% |
726,172
+336,029
| +86% | +$2.18M |
|
11
Geron
GERN
$893M
| $4.58M | 3.81% |
3,251,475
+1,194,838
| +58% | +$1.68M |
|
|
CMPS
12
Compass Pathways
CMPS
$424M
| $4.16M | 3.46% |
+1,485,000
| New | +$4.16M |
|
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$2.25B
| $3.86M | 3.21% |
293,986
+50,900
| +21% | +$669K |
|
14
Avidity Biosciences
RNA
$5.99B
| $3.77M | 3.14% |
+132,744
| New | +$3.77M |
|
15
Solid Biosciences
SLDB
$427M
| $3.53M | 2.93% |
+724,000
| New | +$3.53M |
|
16
Lexeo Therapeutics
LXEO
$259M
| $3.49M | 2.9% |
+867,302
| New | +$3.49M |
|
17
Praxis Precision Medicines
PRAX
$958M
| $3.4M | 2.83% |
80,880
-14,702
| -15% | -$618K |
|
|
TECX
18
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $3.25M | 2.71% |
163,683
+31,461
| +24% | +$625K |
|
19
Korro Bio
KRRO
$217M
| $1.93M | 1.6% |
154,223
+94,500
| +158% | +$1.18M |
|
|
WHWK
20
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $1.53M | 1.27% |
817,939
| – | – |
|
|
ATYR
21
aTyr Pharma
ATYR
$527M
| $1.46M | 1.21% |
287,720
-489,300
| -63% | -$2.48M |
|
22
Monopar Therapeutics
MNPR
$211M
| $1.24M | 1.03% |
+34,537
| New | +$1.24M |
|
23
ProMIS Neurosciences
PMN
$28M
| $646K | 0.54% |
1,334,428
-150,271
| -10% | -$72.7K |
|
|
24
Axsome Therapeutics
AXSM
$6.05B
| – | – |
-72,113
| Closed | -$8.41M |
|
|
BPMC
25
DELISTED
Blueprint Medicines
BPMC
| – | – |
-74,192
| Closed | -$6.57M |
|